Cingulate publishes Phase 3 data for CTx-1301 ADHD candidate
Cingulate has announced that peer-reviewed Phase 3 results for CTx-1301, its once-daily dexmethylphenidate formulation for attention-deficit/hyperactivity disorder, have been published in the Journal of Child and Adolescent Psychopharmacology. The publication, available as open access, covers a randomised, double-blind, placebo-controlled, fixed-dose study in children and adolescents aged 6 to 17.
All three tested dose groups, 18.75 mg, 25 mg, and 37.5 mg, demonstrated statistically significant improvements over placebo on the primary endpoint, change from baseline in ADHD Rating Scale-5 (ADHD-RS-5) scores at week five. The p-values were 0.018, 0.011, and 0.001 for the three doses respectively. Placebo-adjusted effect sizes were 0.737, 0.782, and 1.185 across those groups, giving an overall mean effect size of 0.901 across the study population.
Trial design and efficacy context
Ann Childress, the study's lead investigator, noted that the trial demonstrated "clinically meaningful improvements in ADHD symptoms while maintaining a favorable safety profile," and said the published data would give clinicians expert-reviewed evidence on which to base prescribing decisions.
Raul Silva, Chief Science Officer at Cingulate, highlighted that the effect sizes represent a meaningful separation from placebo rather than mere statistical significance: "Effect size helps quantify how much improvement was observed compared with placebo, providing context on the strength of the treatment response."
CTx-1301 uses Cingulate's proprietary Precision Timed Release platform, which delivers three sequential releases of active ingredient through an erosion barrier layer developed in collaboration with BDD Pharma's Oralogik technology. The design is intended to provide both a rapid onset and full-day coverage from a single tablet. Cingulate is pursuing US regulatory clearance under the FDA's 505(b)(2) pathway, which allows applicants to rely in part on existing safety and efficacy data for a previously approved reference compound.
Regulatory path and competitive landscape
Publication in a peer-reviewed journal is a meaningful step toward an NDA submission under 505(b)(2), but it does not substitute for the full regulatory package. Cingulate will still need to demonstrate to the FDA's satisfaction that the PTR formulation achieves a meaningfully differentiated clinical profile relative to existing dexmethylphenidate and mixed amphetamine salt products already on the market.
The ADHD stimulant segment is well established, with approved once-daily formulations from several large pharmaceutical groups. Cingulate's differentiation case rests on the precision of its release profile, which the company argues avoids drug exposure before the intended release window. Whether that translates into a labelling advantage or a commercial foothold will depend heavily on the NDA review outcome and, subsequently, payer and prescriber uptake.
The US ADHD market involves an estimated 100 million annual prescriptions, according to Cingulate's own figures, and the company notes that fewer than 54% of diagnosed children and teens were actively managing symptoms with medication as of 2022, pointing to a substantial untreated population.
Cingulate has not disclosed a target NDA submission date or commercialisation timeline. The next milestones investors will track are the regulatory engagement schedule and any adult indication data, given that the company has flagged anxiety disorders as a further application for the PTR platform.